SEC Form 4 · accession 0001654954-17-003111
TENAX THERAPEUTICS, INC. · TENX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael B Jebsen
Officer — Interim CEO, President and CFO
Period of report
Apr 3, 2017
Accepted (ET)
Apr 5, 2017 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000034956
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.53 | Apr 3, 2017 | A | 200,000 | A | — | Apr 3, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1This option vests and becomes exercisable in four equal annual installments beginning on April 3, 2018, however, the vesting of the option will accelerate and become fully vested upon the achievement of specified performance goals.